Cover Image
市場調查報告書

慢性腎臟病 (CKD) 治療藥的全球市場:2015年∼2019年

Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 325817
出版日期 內容資訊 英文 103 Pages
訂單完成後即時交付
價格
Back to Top
慢性腎臟病 (CKD) 治療藥的全球市場:2015年∼2019年 Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019
出版日期: 2015年03月11日 內容資訊: 英文 103 Pages
簡介

慢性腎臟病 (CKD) 治療藥的全球市場,預計從2014年到2019年的期間,以1.21%的年複合成長率成長。

本報告提供慢性腎臟病 (CKD) 治療藥的全球市場調查分析、市場概要和基本結構、市場規模趨勢、推動、阻礙市場要素與其影響力、主要企業簡介、今後的市場機會等調查評估。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 產品簡介

  • Aranesp
  • Epogen/Procrit
  • Mircera
  • Renvela
  • Avapro
  • Bystolic

第5章 市場調查手法

  • 市場調查流程
  • 調查手法

第6章 簡介

第7章 疾病概要

  • 病因
  • 流行病學
    • 死亡率
    • 盛行率

第8章 開發平台分析

  • 新的治療方法

第9章 市場形勢

  • 市場概要
  • 市場規模、預測
  • 波特的五力分析

第10章 全球CKD市場區隔:各給藥途徑

  • 口腔
  • SC
  • IV

第11章 全球CKD市場區隔:各作用機制

  • ARB
  • ACEI
  • ESA
  • PH粘合劑
  • 血管擴張劑

第12章 地區區分

  • 南北美洲
    • 市場規模、預測
  • 歐洲、中東、非洲 (EMEA)
  • 亞太地區 (APAC)

第13章 購買標準

第14章 推動市場成長要素

第15章 成長推動因素與其影響

第16章 市場課題

第17章 成長推動因素與課題的影響

第18章 市場趨勢

第19章 趨勢與其影響

第20章 業者情勢

  • 競爭模式
    • 主要新聞
    • M & A
  • 市場佔有率分析
    • CKD治療所採用的主要治療藥的競爭評估
    • Amgen
    • Actavis
    • Johnson & Johnson
    • F. Hoffmann-La Roche
    • Sanofi
  • 其他有潛力的供應商

第21章 主要供應商分析

  • Amgen
    • 主要資料
    • 產業概要
    • 產業區分:各收益
    • 產品系列:各收益
    • 產業區分:各收益的預測
    • 地區區分:各收益
    • 產業策略
    • 主要資訊
    • SWOT分析
  • Actavis
  • Johnson & Johnson
  • F. Hoffmann-La Roche
  • Sanofi

第22章 相關報告

圖表清單

目錄
Product Code: IRTNTR5417

About

According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration.

TechNavio's analysts forecast the Global CKD Drugs market to grow at a CAGR of 1.21 percent over the period 2014-2019.

Covered in this Report

The Global CKD Drugs Market can be divided into two segments: Route of Administration which includes oral, SC, and IV and Mechanism of Action which includes ARBs, ACEIs, ESAs, PH Binders, and Vasodilators. This report covers the present scenario and the growth prospects of the Global CKD Drugs market for the period 2014-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CKD that are available in the market.

TechNavio's report, the Global CKD Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA and APAC regions; it also covers the Global CKD Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Actavis PLC
  • Amgen Inc.
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Sanofi

Other Prominent Vendors

  • Abbott Laboratories
  • Akebia Therapeutics
  • AMAG Pharmaceuticals
  • Cara Therapeutics
  • FibroGen
  • Keryx Biopharmaceuticals
  • Reata Pharmaceuticals
  • OPKO Health
  • Pharmacosmos
  • Raptor Pharmaceuticals
  • Regulus Therapeutics
  • Rockwell Medical
  • Shield Therapeutics
  • Takeda Pharmaceuticals
  • Vifor Pharma Ltd
  • Xenetic Biosciences
  • ZS Pharma

Market Driver

  • Increase in Associated Disorders with CKD
  • For a full, detailed list, view our report

Market Challenge

  • Genericization of Major Brands
  • For a full, detailed list, view our report

Market Trend

  • Approval of New Pipeline Drugs
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Aranesp
    • 04.1.2. Epogen/Procrit
    • 04.1.3. Mircera
    • 04.1.4. Renvela
    • 04.1.5. Avapro
    • 04.1.6. Bystolic

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disease Overview

  • 07.1. Etiology
  • 07.2. Epidemiology
    • 07.2.1. Mortality
    • 07.2.2. Prevalence of CKD

08. Pipeline Analysis

  • 08.1. Emerging Treatment Options

09. Market Landscape

  • 09.1. Market Overview
  • 09.2. Market Size and Forecast
  • 09.3. Five Forces Analysis

10. Segmentation of Global CKD Market by Route of Administration

  • 10.1. Oral
  • 10.2. SC
  • 10.3. IV

11. Segmentation of Global CKD Market by Mechanism of Action

  • 11.1. ARBs
  • 11.2. ACEIs
  • 11.3. ESAs
  • 11.4. PH Binders
  • 11.5. Vasodilators

12. Geographical Segmentation

  • 12.1. CKD Drugs Market in Americas
    • 12.1.1. Market Size and Forecast
  • 12.2. CKD Drugs Market in EMEA Region
    • 12.2.1. Market Size and Forecast
  • 12.3. CKD Drugs Market in APAC Region
    • 12.3.1. Market Size and Forecast

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

  • 20.1. Competitive Scenario
    • 20.1.1. Key News
    • 20.1.2. Mergers and Acquisitions
  • 20.2. Market Share Analysis 2014
    • 20.2.1. Competitive Assessment of Top Drugs Used for CKD Treatment
    • 20.2.2. Amgen
    • 20.2.3. Actavis
    • 20.2.4. Johnson & Johnson
    • 20.2.5. F. Hoffmann-La Roche
    • 20.2.6. Sanofi
  • 20.3. Other Prominent Vendors

21. Key Vendor Analysis

  • 21.1. Amgen
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation by Revenue 2013
    • 21.1.4. Product Portfolio by Revenue 2013
    • 21.1.5. Business Segmentation by Revenue 2012 and 2013
    • 21.1.6. Geographical Segmentation by Revenue 2013
    • 21.1.7. Business Strategy
    • 21.1.8. Recent Developments
    • 21.1.9. SWOT Analysis
  • 21.2. Actavis
    • 21.2.1. Key Facts
    • 21.2.2. Business Description
    • 21.2.3. Business Segmentation
    • 21.2.4. Business Segmentation by Revenue 2012 and 2013
    • 21.2.5. Sales by Geography
    • 21.2.6. Business Strategy
    • 21.2.7. Key Information
    • 21.2.8. SWOT Analysis
  • 21.3. Johnson & Johnson
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation by Revenue 2013
    • 21.3.4. Business Segmentation by Revenue 2012 and 2013
    • 21.3.5. Geographical Segmentation by Revenue 2013
    • 21.3.6. Business Strategy
    • 21.3.7. Recent Developments
    • 21.3.8. SWOT Analysis
  • 21.4. F. Hoffmann-La Roche Ltd.
    • 21.4.1. Key Facts
    • 21.4.2. Business Overview
    • 21.4.3. Business Segmentation
    • 21.4.4. Business Segmentation by Revenue 2012 and 2013
    • 21.4.5. Sales by Geography
    • 21.4.6. Business Strategy
    • 21.4.7. Key Information
    • 21.4.8. SWOT Analysis
  • 21.5. Sanofi SA
    • 21.5.1. Key Facts
    • 21.5.2. Business Description
    • 21.5.3. Business Segmentation
    • 21.5.4. Revenue by Business Segmentation
    • 21.5.5. Revenue Comparison 2012 and 2013
    • 21.5.6. Sales by Geography
    • 21.5.7. Business Strategy
    • 21.5.8. Key Developments
    • 21.5.9. SWOT Analysis

22. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Segmentation of Global CKD Drugs Market
  • Exhibit 2: Market Research Methodology
  • Exhibit 3: Stages of CKD
  • Exhibit 4: Causes of CKD
  • Exhibit 5: Prevalence of CKD among NHANES (US) Participants by CKD Stage 1988-2012
  • Exhibit 6: Global CKD Drugs Market 2014-2019 (US$ billion)
  • Exhibit 7: Drivers and Challenges in Global CKD Drugs Market
  • Exhibit 8: Segmentation of Global CKD Drugs Market by Route of Administration
  • Exhibit 9: Segmentation of Global CKD Drugs Market by Mechanism of Action
  • Exhibit 10: Segmentation of Global CKD Drugs Market by Geography 2014
  • Exhibit 11: Segmentation of Global CKD Drugs Market by Geography 2019
  • Exhibit 12: Segmentation of Global CKD Drugs Market by Geography 2014-2019
  • Exhibit 13: CKD Drugs Market in Americas 2014-2019 (US$ billion)
  • Exhibit 14: CKD Drugs Market in EMEA Region 2014-2019 (US$ billion)
  • Exhibit 15: CKD Drugs Market in APAC Region 2014-2019 (US$ billion)
  • Exhibit 16: Comparison of Percentage of Population Age 65 and Older 2012 and 2050
  • Exhibit 17: Revenue Comparison of Top Drugs Used for Treatment of CKD 2013 (US$ million)
  • Exhibit 18: Epogen: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
  • Exhibit 19: Aranesp: Revenue Comparison and YoY Growth 2011-2013 (US$ million)
  • Exhibit 20: Bystolic: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
  • Exhibit 21: Procrit: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
  • Exhibit 22: Mircera: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
  • Exhibit 23: Renvela: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
  • Exhibit 24: Avapro: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
  • Exhibit 25: Amgen: Business Segmentation by Revenue 2013
  • Exhibit 26: Amgen: Product Portfolio by Revenue 2013
  • Exhibit 27: Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 28: Amgen: Geographical Segmentation by Revenue 2013
  • Exhibit 29: Global CKD Drugs Market Market Business Segmentation 2013
  • Exhibit 30: Global CKD Drugs Market Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 31: Actavis : Sales by Geography (in US$ million)
  • Exhibit 32: Johnson & Johnson: Business Segmentation by Revenue 2013
  • Exhibit 33: Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 34: Johnson & Johnson: Geographical Segmentation by Revenue 2013
  • Exhibit 35: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
  • Exhibit 36: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 37: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 38: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 39: Sanofi SA: Business Segmentation
  • Exhibit 40: Sanofi SA: Revenue by Business Segmentation 2013
  • Exhibit 41: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 42: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Back to Top